Current Report Filing (8-k)
April 01 2019 - 10:56AM
Edgar (US Regulatory)
SECURITIES
AND EXCHANGE COMMISSION
Washington,
DC 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of
the
Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): March 26, 2019
Nutriband
Inc.
Nevada
|
|
000-55654
|
|
81-1118176
|
(State
or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S.
Employer
Identification
No.)
|
121
South Orange Ave., Suite 1500, Orlando, FL
|
|
32801
|
(Address
of Principal Executive Offices)
|
|
(Zip
Code)
|
(407)
377-6695
Registrant’s
Telephone Number, Including Area Code
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
Item
7.01. Regulation FD Disclosure
On
March 26, 2019, Company issued a press release announcing that the European Patent Office has granted full patent protection for
the European Patent Application entitled, “Abuse and Misuse Deterrent Transdermal System” submitted by its subsidiary,
4P Therapeutics. The patent relates to the Company’s proprietary abuse deterrent transdermal technology,
utilized
in the fentanyl transdermal system which is being developed to combat the fentanyl overdose
.
In
accordance with General Instruction B.2 of Form 8-K, the information in Item 7.01 of this Current Report on Form 8-K, including
Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934,
as amended, or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into
any of the Company’s filings under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended,
whether made before or after the date hereof and regardless of any general incorporation language in such filings, except to the
extent expressly set forth by specific reference in such a filing.
Item
9.01. Financial Statements and Exhibits.
(d) Exhibits
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
NUTRIBAND,
INC.
|
|
|
|
Date:
April 1, 2019
|
By:
|
/s/
Gareth Sheridan
|
|
Gareth Sheridan
|
|
Chief
Executive Officer
|
2